News
NDRAW
0.0300
+150.00%
0.0180
ENDRA risks Nasdaq delisting after falling below $2.5 million equity requirement
PUBT · 04/21 12:01
ENDRA Life Sciences Q4 net loss narrows
Reuters · 03/31 20:29
ENDRA FY25 net loss narrows to $7 million; operating expenses fall to $5.8 million
Reuters · 03/31 20:08
ENDRA LIFE SCIENCES INC - ON MARCH 19 ,REDUCED NUMBER OF EMPLOYEES IN ORDER TO REDUCE CASH EXPENDITURES AND EXTEND ITS OPERATIONAL RUNWAY- SEC FILING
Reuters · 03/25 13:25
ENDRA Life Sciences initiates review of strategic alternatives; board evaluates options including investments, mergers, and asset sales
Reuters · 03/25 12:06
ENDRA LIFE SCIENCES INITIATES REVIEW OF STRATEGIC ALTERNATIVES TO MAXIMIZE SHAREHOLDER VALUE
Reuters · 03/25 12:00
ENDRA LIFE SCIENCES INC: CONTINUE TO EXECUTE ON ITS STRATEGIC AND OPERATING INITIATIVES DURING REVIEW PROCESS
Reuters · 03/25 12:00
NASDAQ TRADE HALT <NDRA.O> HALT NEWS PENDING AT 07:55 AM
Reuters · 03/25 11:55
ENDRA TAEUS Liver Device Shows MRI-Level Consistency in Clinical Study
Reuters · 02/26 13:00
ENDRA Life Sciences Reports TAEUS Device Matches MRI Accuracy in Liver Disease Study
Reuters · 12/04/2025 13:01
ENDRA’S TAEUS® LIVER MATCHES MRI-PDFF PERFORMANCE AT KEY CLINICAL THRESHOLDS, POSITIONING DEVICE FOR MASLD/MASH TRIAL USE
Reuters · 12/04/2025 13:00
ENDRA LIFE SCIENCES INC - SECOND FEASIBILITY STUDY FOR TAEUS LIVER DEVICE BEGUN IN LONDON, ONTARIO
Reuters · 12/04/2025 13:00
ENDRA Life Sciences CTO Resigns as CFO Compensation Terms Change
Reuters · 11/28/2025 21:23
ENDRA Life Sciences Reports Positive Feasibility Study Results for TAEUS Liver Fat Quantification Device
Reuters · 11/20/2025 13:01
ENDRA Life Sciences Q3 cash burn declines on cost optimization
Reuters · 11/17/2025 13:10
ENDRA Life Sciences reports third quarter cash burn down 30% to $1.2 million
Reuters · 11/17/2025 13:06
ENDRA LIFE SCIENCES RECAPS MAJOR MILESTONES AND NEW STRATEGIC INITIATIVES, ANNOUNCES THIRD QUARTER 2025 FINANCIAL RESULTS
Reuters · 11/17/2025 13:00
ENDRA Life Sciences Raises $4.9 Million in Private Placement
Reuters · 11/14/2025 21:33
ENDRA Life Sciences Outlines Ongoing Digital Asset Strategy with Plans to Stake HYPE Tokens, Enhance Balance Sheet Diversification, and Explore Further DeFi Opportunities
Reuters · 11/13/2025 13:01
ENDRA LIFE SCIENCES INC - TO PAY LUCID UP TO 3.0% COMMISSION - SEC FILING
Reuters · 10/30/2025 10:11
More
Webull provides a variety of real-time NDRAW stock news. You can receive the latest news about Endra Life Sciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About NDRAW
ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS is focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease and metabolic dysfunction-associated steatohepatitis, chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. TAEUS technology uses a pulsed energy source, specifically, radio frequency (RF), to transmit energy deep into tissue and generate ultrasonic waves based on the tissue composition (or tissue chemistry), differentiating lean and fatty tissues. These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images using its proprietary algorithms.